Patient info Open main menu

Apixaban 2.5 mg film-coated tablets – patient leaflet, side effects, dosage

Last updated: · Text from the MHRA, as of · About this document

Medicine status: Prescription only (POM) Details

Medicine strength:
2.5 mg
Contains active substance:
ATC code:

Patient leaflet - Apixaban 2.5 mg film-coated tablets

1 WHAT APIXABAN IS AND WHAT IT IS USED FOR

Apixaban contains the active substance apixaban and belongs to a group of medicines called anticoagulants. This medicine helps to prevent blood clots from forming by blocking Factor Xa, which is an important component of blood clotting.

Apixaban is used in adults:

  • To prevent blood clots (deep vein thrombosis [DVT]) from forming after hip or knee replacement operations. After an operation to the hip or knee you may be at a higher risk of developing blood clots in your leg veins. This can cause the legs to swell, with or without pain. If a blood clot travels from your leg to your lungs, it can block blood ow causing breathlessness, with or without chest pain. This condition (pulmonary embolism) can be life- threatening and requires immediate medical attention.
  • To prevent a blood clot from forming in the heart in patients with an irregular heartbeat (atrial brillation) and at least one additional risk factor. Blood clots may break off and travel to the brain and lead to a stroke or to other organs and prevent normal blood ow to that organ (also known as a systemic embolism). A stroke can be life-threatening and requires immediate medical attention.
  • To treat blood clots in the veins of your legs (deep vein thrombosis) and in the blood vessels of your lungs (pulmonary embolism), and to prevent blood clots from re-occurring in the blood vessels of your legs and/or lungs.

2 WHAT YOU NEED TO KNOW BEFORE YOU TAKE APIXABAN

Do not take Apixaban

  • If you are allergic to apixaban or any of the other ingredients of this medicine (listed in section 6)
  • If you are bleeding excessively
  • If you have a disease in an organ of the body that increases the risk of serious bleeding (such as an active or a recent ulcer of your stomach or bowel, recent bleeding in your brain)
  • If you have a liver disease which leads to increased risk of bleeding (hepatic coagulopathy)
  • If you are taking medicines to prevent blood clotting (e.g. warfarin, rivaroxaban, dabigatran or heparin), except when changing anticoagulant treatment, while having a venous or arterial line and you get heparin through this line to keep it open, or if a tube is inserted into your blood vessel (catheter ablation) to treat an irregular heartbeat (arrhythmia)

Warnings and precautions

Talk to your doctor, pharmacist or nurse before you take this medicine if you have any of the following:

  • An increased risk of bleeding, such as:

    • bleeding disorders, including conditions resulting in reduced platelet activity
    • very high blood pressure, not controlled by medical treatment
    • you are older than 75 years
    • you weigh 60 kg or less
  • A severe kidney disease or if you are on dialysis
  • A liver problem or a history of liver problems

    • this medicine will be used with caution in patients with signs of altered liver function
  • had a tube (catheter) or an injection into your spinal column (for anaesthesia or pain reduction), your doctor will tell you to take this medicine 5 hours or more after catheter removal
  • If you have a prosthetic heart valve
  • If your doctor determines that your blood pressure is unstable or another treatment or surgical procedure to remove the blood clot from your lungs is planned

Take special care with Apixaban:

  • If you know that you have a disease called antiphospholipid syndrome (a disorder of the immune system that causes an increased risk of blood clots), tell your doctor who will decide if the treatment may need to be changed

If you need to have surgery or a procedure which may cause bleeding, your doctor might ask you to temporarily stop taking this medicine for a short while. If you are not sure whether a procedure may cause bleeding, ask your doctor.

Children and adolescents

This medicine is not recommended in children and adolescents under 18 years of age.

Other medicines and Apixaban

Tell your doctor, pharmacist or nurse if you are taking, have recently taken or might take any other medicines.

Some medicines may increase the effects of Apixaban and some may decrease its effects. Your doctor will decide, if you should be treated with Apixaban when taking these medicines and how closely you should be monitored.

The following medicines may increase the effects of Apixaban and increase the chance for unwanted bleeding:

  • some medicines for fungal infections (e.g. ketoconazole, etc.)
  • some antiviral medicines for HIV/AIDS (e.g. ritonavir)
  • other medicines that are used to reduce blood clotting (e.g. enoxaparin, etc.)
  • anti-in ammatory or pain medicines (e.g. acetylsalicylic acid or naproxen). Especially, if you are older than 75 years and are taking acetylsalicylic acid, you may have an increased chance of bleeding
  • medicines for high blood pressure or heart problems (e.g. diltiazem)
  • antidepressant medicines called selective serotonin re-uptake inhibitors or serotonin norepinephrine re-uptake inhibitors

The following medicines may reduce the ability of Apixaban to help prevent blood clots from forming:

  • medicines to prevent epilepsy or seizures (e.g. phenytoin, etc.)
  • St John's Wort (a herbal supplement used for depression)
  • medicines to treat tuberculosis or other infections (e.g. rifampicin)

Pregnancy and breast-feeding

If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor, pharmacist or nurse for advice before taking this medicine.

The effects of Apixaban on pregnancy and the unborn child are not known. You should not take this medicine if you are pregnant. Contact your doctor immediately if you become pregnant while taking this medicine.

It is not known if Apixaban passes into human breast milk. Ask your doctor, pharmacist or nurse for advice before taking this medicine while breast-feeding. They will advise you whether to stop breast-feeding or to stop/not start taking this medicine.

Driving and using machines

Apixaban has not been shown to impair your ability to drive or use machines.

Apixaban contains sodium

This medicine contains less than 1 mmol sodium (23 mg) per tablet, that is to say essentially 'sodium-free'.

Apixaban contains lactose

If you have been told by your doctor that you have an intolerance to some sugars, contact your doctor before taking this medicine.

3 HOW TO TAKE APIXABAN

Always take this medicine exactly as your doctor or pharmacist has told you. Check with your doctor, pharmacist or nurse if you are not sure.

Dose

Swallow the tablet with a drink of water. Apixaban can be taken with or without food. Try to take the tablets at the same times every day to have the best treatment effect.

If you have difficulty swallowing the tablet whole, talk to your doctor about other ways to take Apixaban. The tablet may be crushed and mixed with water, or 5% glucose in water, or apple juice or apple puree, immediately before you take it.

Instructions for crushing

  • Crush the tablets with a pestle and mortar
  • Transfer all the powder carefully into a suitable container then mix the powder with a little e.g. 30 ml (2 tablespoons), water or one of the other liquids mentioned above to make a mixture
  • Swallow the mixture
  • Rinse the pestle and mortar you used for crushing the tablet and the container, with a little water or one of the other liquids (e.g. 30 ml) and swallow the rinse

If necessary, your doctor may also give you the crushed Apixaban tablet mixed in 60 ml of water or 5% glucose in water, through a nasogastric tube.

To prevent blood clots from forming after hip or knee replacement operations

The recommended dose is one tablet of Apixaban 2.5 mg twice a day. For example, one in the morning and one in the evening. You should take the rst tablet 12 to 24 hours after your operation.

If you have had a major hip operation you will usually take the tablets for 32 to38 days. If you have had a major knee operation you will usually take the tablets for 10 to 14 days.

To prevent a blood clot from forming in the heart in patients with an irregular heartbeat and at least one additional risk factor The recommended dose is one tablet of Apixaban 5 mg twice a day.

The recommended dose is one tablet of Apixaban 2.5 mg twice a day if:

  • you have severely reduced kidney function
  • two or more of the following apply to you:

    • your blood test results suggest poor kidney function (value of serum creatinine is 1.5 mg/dl (133 micromole/l) or greater)
    • you are 80 years old or older
    • your weight is 60 kg or lower

The recommended dose is one tablet twice a day, for example, one in the morning and one in the evening. Your doctor will decide how long you must continue treatment for.

To treat blood clots in the veins of your legs and blood clots in the blood vessels of your lungs

The recommended dose is two tablets of Apixaban 5 mg twice a day for the rst 7 days, for example, two in the morning and two in the evening.

After 7 days the recommended dose is one tablet of Apixaban 5 mg twice a day, for example, one in the morning and one in the evening.

For preventing blood clots from re-occurring following completion of 6 months of treatment

The recommended dose is one tablet of Apixaban 2.5 mg twice a day for example, one in the morning and one in the evening. Your doctor will decide how long you must continue treatment for.

Your doctor might change your anticoagulant treatment as follows:

  • Changing from Apixaban to anticoagulant medicines

    Stop taking Apixaban. Start treatment with the anticoagulant medicines (for example heparin) at the time you would have taken the next tablet.

  • Changing from anticoagulant medicines to Apixaban

    Stop taking the anticoagulant medicines. Start treatment with Apixaban at the time you would have had the next dose of anticoagulant medicine, then continue as normal.

  • Changing from treatment with anticoagulant containing vitamin K antagonist (e.g. warfarin) to Apixaban Stop taking the medicine containing a vitamin K antagonist. Your doctor needs to do blood- measurements and instruct you when to start taking Apixaban.
  • Changing from Apixaban to anticoagulant treatment containing vitamin K antagonist (e.g. warfarin).

    If your doctor tells you that you have to start taking the medicine containing a vitamin K antagonist, continue to take Apixaban for at least 2 days after your rst dose of the medicine containing a vitamin K antagonist. Your doctor needs to do blood-measurements and instruct you when to stop taking Apixaban.

Patients undergoing cardioversion

If your abnormal heartbeat needs to be restored to normal by a procedure called cardioversion, take this medicine at the times your doctor tells you, to prevent blood clots in blood vessels in your brain and other blood vessels in your body.

If you take more Apixaban than you should

Tell your doctor immediately if you have taken more than the prescribed dose of this medicine. Take the medicine pack with you, even if there are no tablets left.

If you take more Apixaban than recommended, you may have an increased risk of bleeding. If bleeding occurs, surgery, blood transfusions, or other treatments that may reverse anti-factor Xa activity may be required.

If you forget to take Apixaban

  • Take the dose as soon as you remember, and take the next dose of Apixaban at the usual time,

    then continue as normal.

If you are not sure what to do or have missed more than one dose, ask your doctor, pharmacist or nurse.

If you stop taking Apixaban

Do not stop taking this medicine without talking to your doctor rst, because the risk of developing a blood clot could be higher if you stop treatment too early.

If you have any further questions on the use of this medicine, ask your doctor, pharmacist or nurse.

4 POSSIBLE SIDE EFFECTS

Like all medicines, this medicine can cause side effects, although not everybody gets them. Apixaban can be given for three different medical conditions. The known side effects and how frequently they occur for each of these medical conditions may differ and are listed separately below. For these conditions, the most common general side effect of this medicine is bleeding which may be potentially life threatening and require immediate medical attention.

The following side effects are known if you take Apixaban to prevent blood clots from forming after hip or knee replacement operations Common side effects (may affect up to 1 in 10 people)

  • Anaemia which may cause tiredness or paleness
  • Bleeding including:

    • bruising and swelling
  • Nausea (feeling sick)

Uncommon side effects (may affect up to 1 in 100 people)

  • Reduced number of platelets in your blood (which can affect clotting)
  • Bleeding:

    • occurring after your operation including bruising and swelling, blood or liquid leaking from the surgical wound/incision (wound secretion) or injection site
    • in your stomach, bowel or bright/red blood in the stools
    • blood in the urine
    • from your nose
    • from the vagina
  • Low blood pressure which may make you feel faint or have a quickened heartbeat
  • Blood tests may show:

    • abnormal liver function
    • an increase in some liver enzymes
    • an increase in bilirubin, a breakdown product of red blood cells, which can cause yellowing of the skin and eyes
  • Itching

Rare side effects (may affect up to 1 in 1,000 people)

  • Allergic reactions (hypersensitivity) which may cause swelling of the face, lips, mouth, tongue and/or throat and difficulty breathing. Contact your doctor immediately if you experience any of these symptoms.
  • Bleeding:

    • into a muscle
    • in your eyes
    • from your gums and blood in your spit when coughing
    • from your rectum
  • Hair loss

    Pharma

    Code

    179 X 850 mm Front

    0212/L-3

    179 X 850 mm Back

Not known (frequency cannot be estimated from the available data)

  • Bleeding:

    • in your brain or in your spinal column
    • in your lungs or your throat
    • in your mouth
    • into your abdomen or space behind your abdominal cavity
    • from a haemorrhoid
    • tests showing blood in the stools or in the urine
    • in the kidney sometimes with presence of blood in urine leading to inability of the kidneys to work properly (anticoagulant-related nephropathy)
    • into a joint causing pain and swelling
  • Skin rash which may form blisters and looks like small targets (central dark spots surrounded by a paler area, with a dark ring around the edge) (erythema multiforme)
  • Blood vessel in ammation (vasculitis) which may result in skin rash or pointed, at, red, round spots under the skin's surface or bruising

The following side effects are known if you take Apixaban to prevent a blood clot from forming in the heart in patients with an irregular heart beat and at least one additional risk factor

Common side effects (may affect up to 1 in 10 people)

  • Bleeding including:

    • in your eyes
    • in your stomach or bowel
    • from your rectum
    • blood in the urine
    • from your nose
    • from your gums
    • bruising and swelling
  • Anaemia which may cause tiredness or paleness
  • Low blood pressure which may make you feel faint or have a quickened heartbeat
  • Nausea (feeling sick)
  • Blood tests may show:

    • an increase in gamma-glutamyltransferase (GGT)

Uncommon side effects (may affect up to 1 in 100 people)

  • Bleeding:

    • in your brain or in your spinal column
    • in your mouth or blood in your spit when coughing
    • into your abdomen, or from the vagina
    • bright/red blood in the stools
    • bleeding occurring after your operation including bruising and swelling, blood or liquid leaking from the surgical wound/incision (wound secretion) or injection site
    • from a haemorrhoid
    • tests showing blood in the stools or in the urine
  • Reduced number of platelets in your blood (which can affect clotting)
  • Blood tests may show:

    • abnormal liver function
    • an increase in some liver enzymes
    • an increase in bilirubin, a breakdown product of red blood cells, which can cause yellowing of the skin and eyes
  • Skin rash
  • Itching
  • Hair loss
  • Allergic reactions (hypersensitivity) which may cause swelling of the face, lips, mouth, tongue and/or throat and difficulty breathing. Contact your doctor immediately if you experience any of these symptoms

Rare side effects (may affect up to 1 in 1,000 people)

  • Bleeding:

    • in your lungs or your throat
    • into the space behind your abdominal cavity
    • into a muscle

Very rare side effects (may affect up to 1 in 10,000 people)

  • Skin rash which may form blisters and looks like small targets (central dark spots surrounded by a paler area, with a dark ring around the edge) (erythema multiforme)

Not known (frequency cannot be estimated from the available data)

  • Blood vessel in ammation (vasculitis) which may result in skin rash or pointed, at, red, round spots under the skin's surface or bruising
  • Bleeding in the kidney sometimes with presence of blood in urine leading to inability of the kidneys to work properly (anticoagulant- related nephropathy)
  • Bleeding into a joint causing pain and swelling

The following side effects are known if you take Apixaban to treat or prevent re-occurrence of blood clots in the veins of your legs and blood clots in the blood vessels of your lungs.

Common side effects (may affect up to 1 in 10 people)

  • Bleeding including:

    • from your nose
    • from your gums
    • blood in the urine
    • bruising and swelling
    • in your stomach, your bowel, from your rectum
    • in your mouth
    • from the vagina
  • Anaemia which may cause tiredness or paleness
  • Reduced number of platelets in your blood (which can affect clotting)
  • Nausea (feeling sick)
  • Skin rash
  • Blood tests may show:

    • an increase in gamma-glutamyltransferase (GGT) or alanine aminotransferase (ALT)

Uncommon side effects (may affect up to 1 in 100 people)

  • Low blood pressure which may make you feel faint or have a quickened heartbeat
  • Bleeding:

    • in your eyes
    • in your mouth or blood in your spit when coughing
    • bright/red blood in the stools
    • tests showing blood in the stools or in the urine
    • bleeding occurring after your operation including bruising and swelling, blood or liquid leaking from the surgical wound/incision (wound secretion) or injection site
    • from a haemorrhoid
    • into a muscle
  • Itching
  • Hair loss
  • Allergic reactions (hypersensitivity) which may cause swelling of the face, lips, mouth, tongue and/or throat and difficulty breathing. Contact your doctor immediately if you experience any of these symptoms
  • Blood tests may show:

    • abnormal liver function
    • an increase in some liver enzymes
    • an increase in bilirubin, a breakdown product of red blood cells, which can cause yellowing of the skin and eyes

Rare side effects (may affect up to 1 in 1,000 people)

  • Bleeding:

    • in your brain or in your spinal column
    • in your lungs

Not known (frequency cannot be estimated from the available data)

  • Bleeding:

    • into your abdomen or the space behind your abdominal cavity
    • in the kidney sometimes with presence of blood in urine leading to inability of the kidneys to work properly (anticoagulant-related nephropathy)
    • into a joint causing pain and swelling
  • Skin rash which may form blisters and looks like small targets (central dark spots surrounded by a paler area, with a dark ring around the edge) (erythema multiforme)
  • Blood vessel in ammation (vasculitis) which may result in skin rash or pointed, at, red, round spots under the skin's surface or bruising

Reporting of side effects

If you get any side effects, talk to your doctor, pharmacist, or nurse. This includes any possible side effects not listed in this lea et. You can also report side effects directly via the Yellow Card Scheme Website: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. By reporting side effects you can help provide more information on the safety of this medicine.

5 HOW TO STORE APIXABAN

Keep this medicine out of the sight and reach of children.

Do not use this medicine after the expiry date which is stated on the carton and on the blister after EXP. The expiry date refers to the last day of that month.

This medicine does not require any special storage conditions.

Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.

6 CONTENTS OF THE PACK AND OTHER INFORMATION

What Apixaban contains

  • The active substance is apixaban. Each tablet contains 2.5 mg of apixaban.
  • The other ingredients are:

    Tablet core

    Mannitol, cellulose microcrystalline, sodium laurilsulfate, croscarmellose sodium and magnesium stearate. Film coat

    Hypromellose, titanium dioxide (E171), lactose monohydrate, macrogol 3350, triacetin and iron oxide yellow (E172).

What Apixaban looks like and contents of the pack

Apixaban 2.5 mg lm-coated tablets are round, biconvex and light yellow.

They are available in blister packs of 10, 20, 28, 30, 56 or 60 lm-coated tablets.

Not all pack sizes may be marketed.

Patient Card: handling information

Inside the Apixaban pack together with the package lea et you will nd a Patient Card or your doctor might give you a similar card. This Patient Card includes information that will be helpful to you and alert other doctors that you are taking Apixaban. You should keep this card with you at all times.

  1. 1. Take the card.
  2. 2.

    Complete the following sections or ask your doctor to do it:

    • Name:
    • Birth Date:
    • Indication:
    • Dose______mg twice daily
    • Doctor's Name:
    • Doctor's telephone:
  3. 3. Fold the card and keep it with you at all times

Marketing Authorisation Holder

Dawa Limited,

5 Sandridge Close,

Harrow, Middlesex,

HA1 1XD, United Kingdom.

Manufacturer

Pharmaceutical Works,

POLPHARMA S.A,

ul. Pelpińska 19,

83-200 Starogard Gdański,

Poland.

This lea et was last revised in July 2026.

Blind or partially sighted?

Is this lea et hard to see or read?

Call 020 8423 2111 to obtain the lea et

in a format suitable for you.

About this document

Source: MHRA - Medicines and Healthcare products Regulatory Agency (products.mhra.gov.uk) · Marketing authorisation: PL 30684/0212

Last revision stated in the text: July 2026 · MHRA data as of 13 October 2026

Found a mistake? Tell us on the contact page.

The information on this site does not replace the advice of a doctor or pharmacist.

Facts about Apixaban 2.5 mg film-coated tablets

Prescription needed? Yes, prescription-only medicine (POM)
Active substance Apixaban
Strength 2.5 mg
Pharmaceutical form Oral tablet
Yellow coloured, round shaped tablets, debossed with "2½" on one side and plain on the other side.
How is it taken Oral
Excipients Lactose Monohydrate Microcrystalline cellulose Croscarmellose sodium Sodium laurilsulfate Povidone, Magnesium stearate, Lactose monohydrate Hypromellose (E464) Titanium dioxide (E171) Triacetin (E1518) Yellow iron oxide (E172)
Is it available? Listed as available (NHS Dictionary of Medicines and Devices – not a record of current supplies)
Shelf life 2 years
Storage This medicinal product does not require any special storage condition.
Drug group (ATC) Antithrombotic agents, direct factor Xa inhibitors
  1. B Blood and blood forming organ drugs
    1. B01 Antithrombotic agents
      1. B01A Antithrombotic agents
        1. B01AF Direct factor Xa inhibitors
          1. B01AF02 apixaban
Marketing authorisation PL 30684/0212, PL 43461/0208 (first authorised 6 October 2026)
Marketing authorisation holder Flamingo Pharma (UK) Ltd.
Codes BNF 02080200

Sources: the MHRA product information (products.mhra.gov.uk) and the NHS Dictionary of Medicines and Devices (dm+d), release 10.2.0 of 19 October 2026, NHS Business Services Authority. Contains public sector information licensed under the Open Government Licence v3.0.